Stay updated on Response to Immunotherapy in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Response to Immunotherapy in Lung Cancer Clinical Trial page.
Latest updates to the Response to Immunotherapy in Lung Cancer Clinical Trial page
- Check4 days agoChange DetectedRevision: v3.3.4 replaces v3.3.3 on the page, indicating a backend/template update rather than changes to study content.SummaryDifference0.1%
- Check11 days agoChange DetectedNo additions or deletions were detected; the study details page content appears unchanged.SummaryDifference0.1%
- Check18 days agoChange Detected- Cholangiocarcinoma removed from the Conditions list for the iCaRe2 study (NCT02012699).SummaryDifference0.1%
- Check25 days agoChange DetectedRecruitment locations across multiple states have been added and several state locations removed, accompanied by an updated Revision: v3.3.3. These changes alter where participants can enroll and whom to contact for the study.SummaryDifference1.0%
- Check32 days agoChange DetectedThe screenshots show only minor UI/layout adjustments with no changes to core study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check39 days agoChange DetectedNo significant additions or deletions were observed in the page content; any visible updates are minor formatting or wording adjustments that do not alter core study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
Stay in the know with updates to Response to Immunotherapy in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Response to Immunotherapy in Lung Cancer Clinical Trial page.